Cancer Therapy Advisor interviewed Dr Dyer about recent study results relating to the retinoblastoma epigenome and an important finding about the timing of retinoblastoma development.
Periocular basal cell carcinomas (pBCCs) have a mean growth rate of 11.2 mm² every 30 days.
In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall surviva.
Researchers have identified a therapeutic target for treating the most common form of eye cancer in adults.
Carboplatin-Induced Ototoxicity Higher than Previously Reported in Children Treated for RetinoblastomaFebruary 28, 2012
Young children with retinoblastoma treated with systemic carboplatin have a higher incidence of ototoxicity than previously reported, calling for routine, thorough, long-term audiologic monitoring, a study in the Journal of Clinical Oncology published online February 27 reported.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC